Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
10 evidence topics · 14 sources
Summary: place in therapy
- Ersodetug is investigational and has no approved indication. The FDA orphan drug designation names the treatment of hypoglycemia due to tumor-associated hyperinsulinism, the FDA breakthrough therapy designation names hypoglycemia caused by tumor HI, and the European Union orphan designation (12 January 2024) names insulinoma.
- The studied use is add-on therapy. The phase 3 upLIFT trial enrolls adults 18 years and older with an islet cell or non-islet cell tumor and biochemical evidence of tumor hyperinsulinism who have not achieved adequate control with usual standard-of-care therapies and require IV glucose infusion and/or parenteral nutrition for 7 days or more. Participants receive ersodetug 9 mg/kg weekly for 8 weeks “as an add-on to standard of care”, then may continue in long-term extension at a dosing frequency of every 2 to 4 weeks. Of the 16 enrolled participants, 12 have malignant islet cell tumors (insulinomas) and 4 have non-islet cell tumors.
- In the expanded access publication, all 8 individuals had received and were refractory to at least 3 standard-of-care therapies (diazoxide, somatostatin analogs, everolimus, and/or corticosteroids), and 6 of 8 were hospitalized at entry. Ersodetug was given intravenously over 30 minutes, and the manufacturer states that hospitalized patients were discharged and received maintenance doses as outpatients. Expanded access continues through a registered program (NCT07262970), with drug supplied at no cost under compassionate use programs.
- The manufacturer describes medical therapy as needed from diagnosis to surgery, when surgery is contraindicated or refused, and chronically in patients who cannot be cured by surgery, and names peri-operative management of solitary or benign tumors and solitary or benign tumors where surgery may not be ideal as potential additional settings. It expects to focus its launch on National Cancer Institutes and academic medical centers, where it believes 60% of patients are managed (about 1,000 prescribers and 300 centers), and expects payers to require prior authorization aligned to the label with a step through diazoxide for patients with insulinoma, with reimbursement through a J-code (buy and bill).
- A 2024 clinical review of insulinoma reports successful use of RZ358 in one patient with malignant insulinoma and severe refractory hypoglycemia.
Studied use: add-on to standard of care in adults requiring continuous intravenous glucose
Points in the disease course at which medical therapy for hypoglycemia is needed: manufacturer statements
Prior therapies and hospitalization of the expanded access population
“All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: inpatient initiation and outpatient maintenance infusions
“Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote